MedTrace Logo

Time-Effect of Montelukast Protection

NCT00935415 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2009-07-09

No results posted yet for this study

Summary

The aim of this study is to verify MNT time of onset of protection against EIB in asthmatic children by evaluating different time intervals between dosing and challenge, after a single-dose and after three days of once a day MNT administration.

Conditions

  • Exercise-Induced Asthma
  • Asthma

Interventions

DRUG

Montelukast

Montelukast 5 mg

DRUG

Placebo

capsules of matching placebo

Sponsors & Collaborators

  • Universita di Verona

    lead OTHER

Principal Investigators

  • Attilio Boner, MD · Universita di Verona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935415 on ClinicalTrials.gov